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Abstract
Context and overview: Chronic cluster headache (CCH) is a debilitating headache disorder with a significant impairment of
the patients’ lives. Within the past decade, various invasive neuromodulatory approaches have been proposed for the
treatment of CCH refractory to standard preventive drug, but only very few randomized controlled studies exist in the
field of neuromodulation for the treatment of drug-refractory headaches. Based on the prominent role of the cranial
parasympathetic system in acute cluster headache attacks, high-frequency sphenopalatine ganglion (SPG) stimulation has
been shown to abort ongoing attacks in some patients in a first small study. As preventive effects of SPG-stimulation have
been suggested and the rate of long-term side effects was moderate, SPG stimulation appears to be a promising new
treatment strategy.
Aims and conclusion: As SPG stimulation is effective in some patients and the first commercially available CE-marked SPG
neurostimulator system has been introduced for cluster headache, patient selection and care should be standardized to
ensure maximal efficacy and safety. As only limited data have been published on SPG stimulation, standards of care based
on expert consensus are proposed to ensure homogeneous patient selection and treatment across international head-
ache centres. Given that SPG stimulation is still a novel approach, all expert-based consensus on patient selection and
standards of care should be re-reviewed when more long-term data are available.
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Introduction
Chronic cluster headache is an excruciating unilateral
short-lasting headache mostly in the first division of the
trigeminal nerve with prominent signs of ictal parasym-
pathetic activation with lacrimation and conjunctival
injection, nasal congestion and rhinorrhoea and sym-
pathetic hypoactivity (1). It causes significant medical
but also economical (2) and social impairment (3,4).
Although most patients respond to acute (triptans,
oxygen and lidocaine) and preventative medication
(verapamil, lithium, topiramate, methysergide and cor-
tisone), a small proportion of patients are drug refrac-
tory or intolerant to established preventive drugs. For
these patients, invasive (such as deep brain stimulation
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of the posterior hypothalamus, occipital nerve stimula-
tion and vagal nerve stimulation) and non-invasive neu-
romodulatory approaches (such as transcutaneous
supraorbital nerve stimulation, transcranial direct cur-
rent stimulation, transcutaneous vagal nerve stimula-
tion and transcranial magnetic stimulation) are
increasingly considered in chronic cluster headache
(5–7). Although no significant diﬀerence between
active stimulation with preset parameters over a
period of 4 weeks compared with no stimulation
could be found in the only randomized controlled
cross-over trial on deep brain stimulation of the poster-
ior hypothalamic area (8), data from the subsequent
open label period along with data from open label stu-
dies and case series (8–14) have shown response rates
(defined as 50% reduction of attacks) of 50% and more
in chronic cluster headache. Similar response rates have
been reported in open label studies of occipital nerve
stimulation (15–19), whereas anecdotal reports do not
allow reliable assessment of the eﬃcacy of vagal nerve
stimulation (20), high cervical spinal cord stimulation
(21) and various non-invasive approaches (see (6,7) for
further review).
The cluster headache armamentarium has recently
been augmented by stimulation of the sphenopalatine
ganglion (SPG). The scientific rationale for targeting
the SPG is based on the close relation between head-
ache and autonomic activation. The clinically observed
peripheral parasympathetic activation of the cranial
autonomic systems with release of vasointestinal pep-
tide (VIP) and acetylcholine during an attack is
hypothesized to activate the trigeminal nociceptors in
turns (22). Its eﬀects are mediated by postganglionic
parasympathetic eﬀerents from the sphenopalatine gan-
glion located in the pterygopalatine fossa (PPF). The
SPG receives preganglionic parasympathetic fibres
from the superior salivatory nucleus in the brain stem
via the greater petrosal nerve which forms the Vidian
nerve together with sympathetic fibres from the carotid
plexus. Although most parasympathetic postganglionic
fibres synapse to postganglionic fibres in the SPG, sym-
pathetic fibres do not. Only a few fibres from the sphe-
nopalatine branches of the maxillary nerve enter the
SPG forming the sensory root. Postganglionic para-
sympathetic fibres innervate the lacrimal gland, the
nasopharyngeal mucous membranes (23) and menin-
geal vessels (24). Sensory trigeminal fibres innervate
areas such as posterior nasopharynx via the lesser pal-
atine nerve.
Upon nociceptive activation of nociceptors belong-
ing to the first division of the trigeminal nerve in a
cluster headache attack, the trigemino-parasympathetic
reflex is activated. Fibres from the trigemino-cervical
complex project to the superior salivatory nucleus
and activate facial parasympathetic eﬀerents (25).
As parasympathetic activation leads to vasodilation
of meningeal arteries, a vicious circle further increas-
ing trigeminal activation has been proposed. As shown
in animal experiments, low-frequency SPG stimulation
around 10 Hz can induce plasma protein extravasation
as a model for neurogenic inflammation (26) and
changes in blood brain barrier (27) and intracerebral
vasodilation (28). In humans, low-frequency stimula-
tion was recently shown to be able to induce attacks in
cluster headache patients (29) raising the question
of whether such attacks are primarily driven by a
centrally mediated parasympathetic activation. Thera-
peutic interventions targeting the SPG have been
attempted for a long time. After alcohol injection
into the SPG, 85% of patients (n¼120) had a rele-
vant decrease of pain (30). Other approaches include
radiofrequency ablation (31) ganglionectomy (32),
and – less invasive – injections of local anaesthetics
(33) or corticosteroids (34) into the SPG. As most of
these procedures oﬀer only temporary benefit, and
most are destructive and non-adjustable, high-fre-
quency stimulation of the SPG has been suggested
as an alternative with promising results in a single
case report (35) and a case series (36). In contrast
with the other neuromodulatory approaches, SPG
stimulation is applied during the acute attack and
not preventatively. Recently, an implantable microsti-
mulator powered and controlled by radio frequency
waves generated by an external remote controller
was developed, whose electrode lead is positioned in
the PPF (Autonomic Technologies, Inc., Redwood
City, CA, USA). A small multicentre randomized
sham-controlled study on the eﬃcacy of acute SPG
stimulation in chronic cluster headache (n¼32) has
shown significant pain relief or pain freedom in 67%
of all attacks treated with full stimulation after 15
minutes compared with subthreshold (7%) and sham
stimulation (7%) (37). Nine of 28 patients in the
experimental period (32%) reported pain relief of
50% or more at 15 minutes stimulation in attacks
with an intensity of 2 or more on a categorical
rating scale (75 attacks were not considered in the
final analysis as their intensity was below 2 out of
4). Of note, the latter analysis referred to a subgroup
of 14 patients only, so results have to be interpreted
with caution. Unexpectedly, a reduction of attack fre-
quency of more than 50% between the baseline and
the parameter adjustment period was reported in 12
out of the 28 patients (43%) during the experimental
period lasting up to 8 weeks, which seemed to be more
pronounced in patients with lower attack frequencies.
Although the incidence of device-related complications
was low, sensory disturbances (81% of patients) and
pain (38%) in the territory of the maxillary nerve were
observed, with the majority of these incidences being
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mild and transient, as would be expected with trans-
oral procedures of this type.
Only very few randomized controlled studies exist in
the field of neuromodulation for the treatment of drug-
refractory headaches and SPG stimulation may be a
promising and safe alternative to the more invasive
strategies in CH given that long-term data are congru-
ent with these short-term observations and that these
findings can be reproduced in larger samples. The SPG
neurostimulator has become commercially available as
a CE marked medical device in EU countries (compli-
ant with AIMD Directive 90/385/EEC and R&TTE
Directive 1999/5/EC in 2012). The CE marking indi-
cates that the manufacturer has verified the product’s
compliance with the above mentioned legislative
requirements such as a harmonized level of safety,
and is therefore mainly driven by safety aspects. As
the ATI device is reimbursed by local healthcare pro-
viders in some countries, there is an unmet need for
defining the standards of care. Therefore, we aimed to
standardize patient selection and propose future long-
term evaluations of its eﬃcacy and safety in drug-
refractory cluster headaches. Secondly, we aimed to
make patient selection and treatment uniform across
international headache centres, and therefore standards
of care are proposed (see Figure 1 for timeline). In the
absence of further randomized controlled studies with a
special focus on long-term data, our recommendations
are based on clinical experience to date and thus repre-
sent expert consensus.
Preoperative management
Choice of neuromodulatory approach
SPG stimulation is a rather recent development whose
eﬃcacy was shown in one of the very few randomized
controlled studies in the field of neuromodulation for
the treatment of drug-refractory headaches. However,
data on eﬃcacy and safety are so far limited to one
study, unlike for occipital nerve stimulation and deep
brain stimulation of the posterior hypothalamus.
Choosing a neuromodulatory approach is a complex,
costly and dynamic process, which may be new for
many headache specialists, and influenced by factors
like balance between eﬃcacy and side eﬀects/risks,
costs, technical pros and cons, local access to the dif-
ferent techniques and devices, patient characteristics,
regulatory and medico-legal issues, as well as recom-
mendations by national guidelines (38). At present, no
predictors of eﬃcacy exist for any mode of neurostimu-
lation in CCH which makes the decision even more
diﬃcult (for recent reviews on current neuromodula-
tory approaches see (5–7), for recent position
paper on neuromodulation issued by the European
Headache Federation see (39)).
Patient selection
Definition of refractory CH (adhering to published criteria). As
SPG stimulation is a novel approach with no published
long-term data at present and an invasive procedure,
eligible patients should be medically refractory or pre-
sent relative or absolute contraindications to conven-
tional acute and/or preventive therapies even if the
main intention is to use SPG stimulation to abort
acute attacks only. As suggested by Goadsby and col-
leagues (40), this includes refractoriness to established
preventatives alone and in combination exceeding the
inclusion criteria of the recent controlled trial on SPG
stimulation which required dissatisfaction with current
treatment (37) (see (41) for current European guidelines
on the treatment of cluster headache) (Table 1).
Additionally, candidates should suﬀer from significant
disability disrupting their socio-professional life.
Withdrawal should be considered first if triptans
and analgesics for acute medication are overused, as
medication overuse headache with increased attack fre-
quency has also been reported in patients with chronic
cluster headache (for review see (42)), and other neuro-
modulatory approaches were less eﬃcient in patients
with medication overuse. As their application is not
yet standardized, occipital nerve blocks or suboccipital
injections of steroids should have been tried before-
hand, based on several studies that have shown their
eﬃcacy as a preventative treatment (43–45). However,
repeated application in short-time intervals may be
problematic.
If interictal headaches are frequent or persist con-
tinuously, indomethacin should be given to rule out





















Figure 1. Timeline for neurostimulator implantation in drug-refractory cluster headache (CH) targeting the sphenopalatine ganglion
(SPG). a: year; CT: computed tomography; CBCT: cone beam computed tomography.
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Further inclusion and exclusion criteria. Relevant inclusion
and exclusion criteria are listed in Tables 2 and 3
including the following:
a. a documented history of refractory cluster headache
for at least 2 years before the implantation;
b. headache meets the current ICHD criteria for
chronic cluster headache (see Use in episodic cluster
headache);
c. detailed headache diary (on daily basis) for at least
1 month: number of attacks, severity and mean
duration of attacks, consumption of rescue medica-
tion, circadian (and circannual) rhythmicity, res-
ponse to the various preventatives including dosage,
duration of intake and response;
d. attacks are side-locked or occur predominantly
(>90% of the time) on one side. If this is not the
case a bilateral approach such as bilateral occipital
nerve stimulation should be considered;
e. significant disability and socio-professional impair-
ment as measured by MIDAS (46) and/or HIT-6
(47);
f. patient is able to comprehend and comply with the
instructions on how and when to use the device and
will present to the headache specialist for regular
follow-up visits.
It is strongly recommended to treat only patients
included in either register studies or patient registries
Table 1. Definition of refractory cluster headache (modified
from (50,51)).
– ICHD-II criteria for cluster headache are met
– Significant interference with function or quality of life
– Failed adequate trials of preventative medication, alone or in
combination (failure is defined as no therapeutic or unsatis-
factory eect, intolerable side eects or contraindications to
use; adequate is defined as appropriate dose and appropriate
length of time)
– Consideration of medication overuse








Table 2. Inclusion criteria for stimulation of the sphenopalatine
ganglion.
Inclusion criteria
– Refractory chronic cluster headache (see Table 1) with a
documented headache history of at least 2 years (for patients
with episodic cluster headache, see text)
– Patient suffers from a substantial number of weekly attacks
– Attacks have been documented in a diary for the recent
month
– Severe psychosocial impairment (as measured by HIT-6 or
MIDAS)
– Attacks are side locked or have occurred predominantly
(>90%) on the current side for the last 12 months
– Ability to distinguish cluster headaches from other headaches
if concomitantly present
– Unremarkable MRI of the brain
– Implantation at a site with experience in headache diagnosis
and treatment and a maxillofacial surgery team with specific
training and expertise in implantation of SPG stimulators
Table 3. Exclusion criteria for stimulation of the sphenopala-
tine ganglion.
Exclusion criteria
– Lateral opening of pterygopalatine fossa is too narrow for
placement of the electrode lead as confirmed on an MRI, CT
or CBCT scan of the region
– Destructive or ablative procedures to the SPG with lasting
deficit
– Patient has undergone facial surgery in the area of the pter-
ygopalatine fossa or zygomaticomaxillary buttress ipsilateral
to the planned implant site within the last 4 months or will
undergo it in the next months
– Presence of active periodontal disease, open carious lesions,
pericoronitis, dental abscess or other dental related infec-
tious process in the ipsilateral maxillary region to be
operated
– Presence of other active infectious process, such as osteo-
myelitis in the jaws
– Relevant osteodestructive disorder
– Malignancy in and/or radiotherapy in the facial region within
the last 6 months
– Woman at childbearing age who is pregnant, breastfeeding or
not using adequate contraception
– Other implantable devices using a sense amplifier, such as
pacemakers or defibrillator without prior confirmation of
compatibility by the manufacturer
– CSF shunt
– Withdrawal has not been considered in suspected medication
overuse
– Severe psychiatric disorder other than reactive depression
(such as somatoform or personality disorder)
– Serious medical condition likely requiring interventions in the
facial region or frequent craniocervical MRIs (although MRI
safety has been shown up to 1.5 T, image quality can be
impaired due to artefacts)
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to avoid data loss of long-term eﬃcacy and safety. To
better assess SPG-related eﬃcacy, patients should be
able to maintain stable medication throughout the
titration and therapy evaluation period. It should be
noted that patients on the waiting list for implantation
may remit spontaneously (9).
Use in controlled studies. To ensure comparability with
other studies on the acute and/or preventive eﬃcacy
of SPG stimulation and other neuromodulatory
approaches, outcome measures for future studies
should be homogenous. Apart from the guidelines on
the design of controlled trials published in 1995 (48), a
position paper with recommendations for future studies
has recently been published by the European Headache
Foundation (39) paving the way for an international
consensus on the design of controlled trials on neuro-
modulatory approaches.
Use in episodic cluster headache. As a result of a paucity of
data on the eﬃcacy of SPG stimulation in episodic CH,
no general recommendation can be given at this time.
However, SPG stimulation may be indicated if the
following criteria are met: the headache is well docu-
mented over the previous 2 years, refractory according
to Table 1, causes high disability, occurs with several
daily attacks poorly responsive to oxygen and triptans
(or contraindications to use the latter because of car-
diovascular conditions) or major dissatisfaction with
conventional treatment, and active periods should usu-
ally last for at least 3–6 months and occur with at least
yearly episodes.
Preoperative clinical oral examination. Oral examination
should be conducted timely ahead of the implant proced-
ure to exclude dental disease and other oral conditions
that might compromise safe surgery. If any such condi-
tions are found, the patientmust undergo relevant dental
treatment, typically sub- and supragingival scaling, cor-
rection of oral hygiene, extraction of carious teeth that
cannot be restored, removal of partially erupted maxil-
lary third molars with or without pericoronitis.
Preoperative imaging. Midfacial CT scans or cone beam
computed tomography (CBCT) need to be evaluated by
the implanting surgeon to:
a. ensure accessibility of the PPF;
b. exclude signs of regional infections (maxillary sinus,
maxillary bone and teeth);
c. exclude signs of osteodestructive disease (such as
osteoporosis or osteonecrosis);
d. exclude signs of other preexisting osseous defects
(such as posttraumatic defects, dental or surgical
treatment).
If any dental pathology is suspected, dental x-ray
films of premolars and molars and/or panoramic
views on the side to be operated should be per-
formed preoperatively as requested by the implanting
surgeon.
Patients with severe osteoporosis (especially with iat-
rogenic osteoporosis caused by long-term steroid treat-
ment) or extreme maxillary atrophy should only be
considered with caution as the risk for misplacement
and infection may increase.
Predictive factors of success. At present, factors predictive
of acute and/or preventive response to SPG stimulation
are unknown. It is intriguing to assume such a predict-
ive role for SPG blocks; however, there are no data to
support such a role at present. It should be kept in mind
that – despite an equally intuitive relation – occipital
nerve blocks (respectively suboccipital injections of
steroids) failed to show such a predictive role for eﬀect-
ive occipital nerve stimulation.
Organizational requirements including site
structure
As stated in Patient selection, sites performing implant-
ations should have:
a. Experience in the management of patients with
refractory cluster headaches and an interdisciplinary
setup.
b. Surgeons with particular expertise in interventions
of the mid-face, anterior skull base and infratem-
poral fossa (such as maxillofacial or otolaryngolo-
gist surgeons) who have undergone certified cadaver
training by the company and may be assisted by
visiting physicians in centres with distinct surgical
expertise in SPG surgery.
c. The means to ensure long-term follow-up of
implanted patients either on-site or by other quali-
fied centres in a scientific network.
Determination of implant size and target position
Based on the preoperative CT or CBCT, a custom 3D
reconstruction is provided by the manufacturer to:
a. determine implant size (approximate lengths of cur-
rently available SPG stimulators: short 3.6 cm,
medium 4.4 cm, long 5.2 cm, extra long 6.0 cm);
b. determine and visualize the target position
of the electrode tip superimposed on an anterior
to posterior reconstruction to guide the implanting
surgeon during placement of the neurostimulator in
this complex anatomical region. The target position
is the putative location of the SPG usually posterior
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to the middle nasal turbinate close to the Vidian
canal located in the superiomedial part of the
PPF, whereas the foramen rotundum as exit point
of the maxillary nerve is typically located in the
superolateral PPF. The target’s reference to the
facial midline (lateral) and the plane of the hard
palate (vertical) is recorded for later intraoperative
navigation.
Current specifications for preoperative imaging are
as follows: slice thickness of 0.5–1.0mm, reconstruction
of 0.5–1.5mm, helical or volume acquisition, gantry tilt
of 0", contiguous slicing and a pitch of 1:1 or 1:1.5
(please refer to the manufacturer for more detailed
and latest information).
Intra- and perioperative management
Choice of anaesthesia
The implantation procedure itself involves incision of
the oral mucosa, preparation of tissue from the maxilla
to place the electrode lead in the pterygopalatine fossa
and fixing the stimulator body to the maxillary bone
(infra-zygomatic buttress) (see Figure 2(a), part 3). Like
similar operations in the field of oral and maxillofacial
surgery, this can theoretically be done under local
anaesthesia of the oral mucosa and the PPF.
However, positioning the device subperiostally is diﬃ-
cult, and some cases need repeated repositioning
attempts. The procedure requires the patients to lie
immobile during the implantation procedure and the
fluoroscopy to prevent tissue damage to the SPG.
Therefore, it is recommended to perform the implant-
ations under general anaesthesia.
Intra- or perioperative antibiotic treatment
and oral decontamination
As the neurostimulator is a foreign body inserted
through the oral cavity, a single shot of an appropriate
antibiotic with an extended spectrum to anaerobes
(such as aminopenicillines with betalactamase inhibi-
tors, clindamycin or newer macrolides) according to
local guidelines or standards should be given preopera-
tively to reach suﬃcient levels at the beginning of the
operation (49).
Oral decontamination prior to surgery should
include a chlorhexidine 0.1% mouth rinse and scrub-
bing with swabs.
Surgical procedure
A trans-oral approach is recommended with an inci-
sion in the gingival crevice of the maxilla and appro-
priate relaxation incisions. A neurostimulator with an
Figure 2. Sphenopalatine ganglion (SPG) neurostimulator. (a) Anterior-posterior x-ray showing the electrode lead in the
pterygopalatine fossa (1), the body of the neurostimulator with the microprocessor and the RF-antenna (2) and the fixation
plate (3). (b) Lateral view of SPG stimulator (modified after (6)).
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appropriate length as determined on preoperative ima-
ging analysis of the intended implant location is
inserted after blunt subperiosteal preparation of a
path for the electrode lead into the pterygopalatine
fossa with customized surgical tools provided by the
manufacturer. Prior to insertion, the neurostimulator
should be placed into a non-metallic bowl filled with
ice-cold sterile water to enhance rigidity of the lead tip
and, consequently, impedances should be tested at
1mA. The bone plate of the neurostimulator is adapted
individually by bending the material. Once the correct
position is confirmed by fluoroscopy or 3D x-ray, the
body of the stimulator is fixed with two or three bone
screws to the zygomatic process of the maxillary bone
such that the neurostimulator is placed on the posterior
maxilla, medial to the zygoma and not obstructing lat-
eral/medial excursions of the mandibular ramus (a
detailed manuscript on surgical aspects of SPG
implantation is under preparation) (Figure 1).
Intraoperative assessment of implant position
Imaging techniques. During blunt preparation and after
placement of the neurostimulator, anterior-posterior
and lateral x-rays (fluoroscopy) should be performed
and compared with the target position on the recon-
structed 3D image. As a result of the distortion of fluor-
oscopy, a reference to linear measurements (lateral to
face midline on the frontal view, and cranial to the
palatal plane on the lateral view) may be obtained
by placing a coin or similar object with a known
diameter fitted with a suture (for safe removal) in the
rhinopharynx close to the film plane of the target,
allowing for calculation of actual linear measurements
with reasonable accuracy. No matter of projection, a
coin will reflect its true diameter. After final placement
of the electrode lead in the pterygopalatine fossa,
the exact location should be confirmed by appropriate
imaging (3D fluoroscopy is preferable over conven-
tional anterior-posterior and lateral images as they
allow a more detailed localization of the electrode
lead in relation to the Vidian canal and the foramen
rotundum).
Test stimulation and impedance check. As the implantation
should be carried out under general anaesthesia, no
mapping of paresthesias evoked by bipolar high fre-
quency stimulation of diﬀerent electrode contacts can
be performed intraoperatively. The predictive value of
short-term, low-frequency stimulation to provoke para-
sympathetic activation (28) is uncertain and no data
have been published yet. After the correct position of
the neurostimulator is confirmed by either fluoroscopy
or 3D imaging and the stimulator is fixed, a final
impedance check is mandatory to rule out periproce-
dural damage to the stimulator.
Analgesic treatment of patient
In the original publication local pain was reported
perioperatively in 38% of the patients and headache
in 9% (37). As most patients find it diﬃcult to dis-
tinguish between pain caused by the implant-
ation itself and a prolonged cluster headache attack,
postoperative analgesia should pragmatically rely on
both:
a. abortive medication specific for cluster headache
such as sumatriptan s.c. 6mg (consider that inject-
able triptans are not available routinely in most
post-anaesthesia care units) and high-flow oxygen
on face masks (consider that post-op the face
mask must not be held with too much pressure
against the face);
b. conventional postoperative established analgesic
regimes (such as paracetamol, NSAIDs alone or
in combination with opioids) adhering to local
standards.
Pre-discharge imaging
To safely exclude misplacement of the stimulator with
the possibility of an early revision, a CT or CBCT is
recommended before discharge.
Post-discharge dental precautions
Preventive and restorative dentistry can be undertaken
without particular precautions except:
a. if extraction of molar teeth, root resection or other
oral surgery in the operated side must be executed,
this should be performed by an oral and maxillo-
facial surgeon who is familiar with the presence of
the SPG neurostimulator;
b. local anaesthetics for dental procedures in the
side of the upper jaw where the implant has
been installed should be restricted to infiltrations.
Block anaesthesia involving injection around the
SPG neurostimulator should be avoided (tuber
region).
c. the patient should rinse with chlorhexidine 0.12%
twice a day in the first week. The sutures are usually
removed 7–12 days postoperatively.
The patient should be provided with an implant
identification card containing relevant details about
the device itself and the implanting and treating
physician.
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Postoperative management
Stabilisation period (4 weeks)
Wound healing is a dynamic process. Residual blood
and ichor can attenuate stimulation eﬃcacy by reducing
local current density and focality due to enlarged elec-
trical fields around the electrodes and altered imped-
ances. As a result of ongoing resorption, electrical
fields and thus stimulation parameters can vary widely,
so that frequent adjustments are necessary. Unless the
patient is exceptionally aﬀected and frequent oﬃce visits
are feasible, a healing period of 4 weeks is recommended.
However, patients can be trained to couple their remote
controller with the neurostimulator at that stage.
Titration/dose finding (mostly 4–8 weeks)
During the titration period, oﬃce visits should be
performed biweekly. During the oﬃce visits:
a. impedances should be checked;
b. communication between the neurostimulator and
the remote control should be checked;
c. a paresthesia and/or autonomic symptom mapping
should be performed until an electrode combination
is found which generates a tingling sensation in the
soft palate and the root of the nose as suggested by
Narouze and co-workers (30), or autonomic symp-
toms such as lacrimation are seen, indicating eﬀer-
ent activation of the parasympathetic system.
These procedures should be performed by medical
personnel with special training only who should rely
on medical engineering expertise (granted by the manu-
facturer) wherever necessary. If medico-legally accept-
able, standard procedures can be delegated to a trained
study nurse.
Paresthesia mapping and appropriate documentation. During
paresthesia mapping, various combinations of elec-
trodes should be tried to elicit paresthesias in the soft
palate and deep in the nasopharynx. The mapping
should be documented for the following parameters
(electrode combination with polarity, region of pares-
thesia, presence of autonomic symptoms or evoked
pain during test stimulation, other stimulation
parameters such as frequency, amplitude and pulse-
width). Eﬀective stimulation depends on an optimum
combination of electrode contacts, the polarity of each
electrode and the right stimulus settings (amplitude,
frequency, pulse-width and ramp time). The choice of
electrode contacts should be based on the paresthesia
mapping and postoperative CT or CBCT scans. When
adjusting polarity, it should be considered that current
density is highest at the cathode. The following stand-
ard parameters have been used in the Pathway-CH1
trial as basic settings: frequency 120Hz, pulse width
355ms and a ramp time of 20–25 seconds. The ampli-
tude should be high enough to evoke a continuing level
of paresthesias deep in the nasopharynx (30), but well
below the pain threshold.
Training of patients on the use of the remote controller. As the
neurostimulator is programmed and supplied with
energy by a radiofrequency coil in the remote control-
ler, continuous communication between both is critical
as well. Therefore, the patient should at first be trained
to identify the most eﬀective position of the radiofre-
quency coil in relation to the neurostimulator. Then,
the patient should learn to control the stimulation
intensity by up- and downregulating the stimulation
amplitude with the remote controller until the patient
perceives paresthesias deep in the nasopharynx. As the
device ramps the amplitude to the maximum within a
predefined period, the patient should learn to adjust the
amplitude so that maximum paresthesias are perceived
without significant discomfort or pain. Patients should
be encouraged to stimulate each attack for 15minutes
(or at least 3minutes longer than it takes to abort
attacks) with the preset parameters, and record eﬃcacy
of stimulation and side eﬀects in the headache diary
already in use.
Therapeutic stimulation and follow-up
When the stimulation parameters are optimized
and acute stimulation suﬃciently relieves acute attacks
(or attack frequency diminishes after regular SPG
stimulation), patients should be moved to the thera-
peutic phase. They should be encouraged to start
stimulation as soon as an attack begins, as some
patients report decreased eﬃcacy of SPG neurostimula-
tion if attacks have reached a severe or very severe
intensity.
In this treatment phase, patients should be seen on
a monthly basis in the first 3 months, then every 3
months for the first year. In selected cases with good
response, these intervals can be stretched at an earlier
time point. Telephone visits can be performed in these
cases.
If SPG stimulation provides acute (and/or prophy-
lactic) eﬃcacy, stepwise tapering of preventative medi-
cation should not be commenced before a sustained
response has been observed for at least 1–2 months.
As suggested for the pre-implantation period, treatment
eﬃcacy should be continuously monitored and docu-
mented with an appropriate headache diary recording
stimulation eﬃcacy and frequency and validated tests
for impairment. Preventive stimulation (stimulation
outside of an attack) may also be attempted, for exam-
ple for 15minutes every morning.
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MRI safety
According to the manual provided by the manufac-
turer, non-clinical testing has revealed that the implan-
table microstimulator is MRI conditional and can be
used safely in static magnetic fields of 1.5 Tesla with a
spatial gradient field of 8Tesla/meter and a maximum
whole body averaged specific absorption rate (SAR) of
2W/kg for 15minutes of scanning.
Side effects and complications
Stimulation related side effects
Side eﬀects of stimulation were mostly mild and
required no specific action (36). Paresthesias deep in
the nasopharynx including the soft palate, which
seem to be predictive of stimulation, are sometimes
perceived as uncomfortable by patients. In these
cases, the patients should be advised to decrease the
amplitude.
Implant and procedure related adverse events
Misplacement of electrode lead. Misplacement of the elec-
trode has been reported in three patients so far (one
patient with early lead migration) (36), although this
did not result in damage to surrounding structures
extending the reported side eﬀects. Red flags for mis-
placement are:
a. very low (can indicate excessive fluid) and very high
impedance readings (indicate placement in air-filled
cavities such as the maxillary sinus);
b. inability to generate adequate paresthesia in the pre-
ferred location deep in the nasopharynx;
c. missing therapeutic eﬀect despite intense test stimu-
lation.
In these cases, CT scans or CBCTs of the correspond-
ing region should be obtained to ascertain leadmisplace-
ment. If the lead causes no acute potential harm in its
present location, it has to be discussed with the patient
whether he/she would like to simply explant the neuro-
stimulator or wishes a reimplantation. In case of the
latter, this depends on local complications (such as per-
foration of the lateral wall of the maxillary sinus),
whether explantation and reimplantation are performed
in the same session or whether a healing period of 3-6
months is necessary.
Suspected or manifest infection. In case of suspected infec-
tion, the incision site should be inspected, and
imaging (CT scan, CBCT and, if necessary, bone scin-
tigraphy) and lab tests (leucocyte count, CRP, ESR)
obtained. Antibiotic treatment seems to be suﬃcient
(36) and should be tried before explantation of the
stimulator.
No efficacy despite optimization of stimulation parameters. If
no clinical benefit is achieved with acute SPG stimula-
tion, a complete paresthesia mapping is recommended
with the aim of establishing parameters that induce
nasopharyngeal paresthesias. If this cannot be
achieved, misplacement of the stimulation electrode or
device failure should be considered. If nasopharyngeal
paresthesias can be evoked, the following issues should
be checked:
a. Does increasing the stimulation amplitude, the pulse
width (up to 480), and/or the frequency (up to
180Hz) increase eﬃcacy?
b. Does the patient start stimulation in the early phase
of an attack?
c. Is the communication between the remote controller
and the neurostimulator stable and above an aver-
age of 50%? If not, the patient should be trained
again to couple the neurostimulator with the remote
controller.
d. Does the patient stimulate long enough (i.e. at least
3–5minutes beyond resolution of the attack)?
e. Does the stimulation ‘tilt’ (reaching the maximum
amount of available voltage) above a certain ampli-
tude? If so, the power level of the remote controller
should be adjusted.
Sensory disturbance. Sensory deficits in the distribution
of V2 (including intraoral sensory deficits) were com-
monly reported ranging from mild hypo- to anaesthesia
and resolved or improved dramatically over time (36).
Because of their remitting nature, there is usually
no need for further action. Further correlates of neuro-
pathic injury include allodynia, evoked dysaesthe-
sias and painful sensations. If not remitting or
uncomfortable, they can be treated with preventative
drugs used in the management of neuropathic pain,
such as gabapentin, pregabaline, duloxetine and ami-
triptyline (50).
Side-shift of attack
Side-shifts of attacks within or between bouts occur in
up to 19% of patients with cluster headache (51),
although this is uncommon during an attack. It has
also been reported in patients with cluster headache
who received eﬀective unilateral neurostimulation on
the clinically aﬀected side in unilateral deep brain (51)
and occipital nerve stimulation (18) requiring implant-
ation of an additional neurostimulation system on the
contralateral side. In patients with a unilateral SPG
stimulator and side-shift from the stimulated to the
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contralateral side, preventive drug treatment should be
intensified if possible and patients should followed up
for at least 12 months before an additional implant is
considered on the contralateral side.
Clinical implications
. Recently, evidence has emerged that stimulation of the sphenopalatine ganglion (SPG) eﬀectively aborts
acute cluster headache attacks in some patients.
. Patient selection and patient care should be standardized to ensure maximal eﬃcacy and safety.
. Therefore standards of care are proposed based on international expert consensus to ensure uniform patient
selection and treatment across international headache centres.
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